Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pere N Roset

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Heart (British Cardiac Society)|May 18, 2012
Cilostazol in NICE guidelineSergi Bellmunt, Pere N Roset, Jose R Escudero
Journal of Clinical Pharmacology|December 19, 2003
Putting clinical pharmacology in context: the use of popular moviesMagí Farré, Fèlix Bosch, Pere N Roset, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|August 21, 2004
Stereochemical analysis of 3,4-methylenedioxymethamphetamine and its main metabolites in human samples including the catechol-type metabolite (3,4-dihydroxymethamphetamine)Nieves Pizarro, Magí Farré, Mitona Pujadas, et al.
Therapeutic Drug Monitoring|July 2, 2004
Human pharmacology of MDMA: pharmacokinetics, metabolism, and dispositionRafael de la Torre, Magí Farré, Pere N Roset, et al.
JAMA|April 17, 2003
Modulation of the immune system in cannabis usersRoberta Pacifici, Piergiorgio Zuccaro, Simona Pichini, et al.
The Journal of Pharmacology and Experimental Therapeutics|September 25, 2007
Pharmacological interaction between 3,4-methylenedioxymethamphetamine (ecstasy) and paroxetine: pharmacological effects and pharmacokineticsMagí Farré, Sergio Abanades, Pere N Roset, et al.
The Journal of Pharmacology and Experimental Therapeutics|December 26, 2001
3,4-Methylenedioxymethamphetamine (ecstasy) and alcohol interactions in humans: psychomotor performance, subjective effects, and pharmacokineticsCándido Hernández-López, Magí Farré, Pere N Roset, et al.
European Journal of Clinical Pharmacology|July 26, 2005
MDMA (ecstasy) pharmacokinetics in a CYP2D6 poor metaboliser and in nine CYP2D6 extensive metabolisersRafael de la Torre, Magí Farré, Brian O Mathúna, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 15, 2004
Paroxetine inhibits acute effects of 3,4-methylenedioxymethamphetamine on the immune system in humansRoberta Pacifici, Simona Pichini, Piergiorgio Zuccaro, et al.
Clinical Pharmacokinetics|May 25, 2005
Contribution of cytochrome P450 2D6 to 3,4-methylenedioxymethamphetamine disposition in humans: use of paroxetine as a metabolic inhibitor probeMireia Segura, Magí Farré, Simona Pichini, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Heart (British Cardiac Society)|May 18, 2012
Cilostazol in NICE guidelineSergi Bellmunt, Pere N Roset, Jose R Escudero
Journal of Clinical Pharmacology|December 19, 2003
Putting clinical pharmacology in context: the use of popular moviesMagí Farré, Fèlix Bosch, Pere N Roset, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|August 21, 2004
Stereochemical analysis of 3,4-methylenedioxymethamphetamine and its main metabolites in human samples including the catechol-type metabolite (3,4-dihydroxymethamphetamine)Nieves Pizarro, Magí Farré, Mitona Pujadas, et al.
Therapeutic Drug Monitoring|July 2, 2004
Human pharmacology of MDMA: pharmacokinetics, metabolism, and dispositionRafael de la Torre, Magí Farré, Pere N Roset, et al.
JAMA|April 17, 2003
Modulation of the immune system in cannabis usersRoberta Pacifici, Piergiorgio Zuccaro, Simona Pichini, et al.
The Journal of Pharmacology and Experimental Therapeutics|September 25, 2007
Pharmacological interaction between 3,4-methylenedioxymethamphetamine (ecstasy) and paroxetine: pharmacological effects and pharmacokineticsMagí Farré, Sergio Abanades, Pere N Roset, et al.
The Journal of Pharmacology and Experimental Therapeutics|December 26, 2001
3,4-Methylenedioxymethamphetamine (ecstasy) and alcohol interactions in humans: psychomotor performance, subjective effects, and pharmacokineticsCándido Hernández-López, Magí Farré, Pere N Roset, et al.
European Journal of Clinical Pharmacology|July 26, 2005
MDMA (ecstasy) pharmacokinetics in a CYP2D6 poor metaboliser and in nine CYP2D6 extensive metabolisersRafael de la Torre, Magí Farré, Brian O Mathúna, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 15, 2004
Paroxetine inhibits acute effects of 3,4-methylenedioxymethamphetamine on the immune system in humansRoberta Pacifici, Simona Pichini, Piergiorgio Zuccaro, et al.
Clinical Pharmacokinetics|May 25, 2005
Contribution of cytochrome P450 2D6 to 3,4-methylenedioxymethamphetamine disposition in humans: use of paroxetine as a metabolic inhibitor probeMireia Segura, Magí Farré, Simona Pichini, et al.
Pageof 2